Epigenetics in Ascending Thoracic Aortic Aneurysm and Dissection

Adeline Boileau, MSc¹  Mark E. Lindsay, MD, PhD²  Jean-Baptiste Michel, MD, PhD³  Yvan Devaux, PhD¹

¹ Cardiovascular Research Unit, Luxembourg Institute of Health, Luxembourg, Luxembourg
² Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
³ UMRS 1148, INSERM, Paris 7-Denis Diderot University, Hôpital Xavier Bichat, Paris, France

AORTA 2018;6:1–12.

Abstract

Thoracic aortic aneurysm (TAA) is an asymptomatic and progressive dilatation of the thoracic aorta. Ascending aortic dissection (AAD) is an acute intraparietal tear, occurring or not on a pre-existing dilatation. AAD is a condition associated with a poor prognosis and a high mortality rate. TAA and AAD share common etiology as monogenic diseases linked to transforming growth factor β signaling pathway, extracellular matrix defect, or smooth muscle cell protein mutations. They feature a complex pathogenesis including loss of smooth muscle cells, altered phenotype, and extracellular matrix degradation in aortic media layer. A better knowledge of the mechanisms responsible for TAA progression and AAD occurrence is needed to improve healthcare, nowadays mainly consisting of aortic open surgery or endovascular replacement. Recent breakthrough discoveries allowed a deeper characterization of the mechanisms of gene regulation. Since alteration in gene expression has been linked to TAA and AAD, it is conceivable that a better knowledge of the causes of this alteration may lead to novel theranostic approaches. In this review article, the authors will focus on epigenetic regulation of gene expression, including the role of histone methylation and acetylation, deoxyribonucleic acid methylation, and noncoding ribonucleic acids in the pathogenesis of TAA and AAD. They will provide a translational perspective, presenting recent data that motivate the evaluation of the potential of epigenetics to diagnose TAA and prevent AAD.

Keywords
► noncoding RNAs
► histone acetylation
► DNA methylation

Aortic progressive dilation (aneurysm) is a potentially life-threatening condition that puts patients at risk of aortic dissection or rupture, a devastating clinical event with high mortality. Most aneurysms are painless and cause no sympotmatology to alert the patient or clinician to the associated risk. Unfortunately, the hidden nature of progressive extracellular matrix (ECM) defect (with or without dilation) means that often the diagnosis is only made at the time of an aortic dissection. Thousands of deaths annually can be attributed to aortic aneurysms and dissections.¹

Epigenetics can be defined as stable heritable traits independent of changes in deoxyribonucleic acid (DNA) sequence. In many cardiovascular disorders, significant epigenetic modifications have been shown to affect disease development or progression. Work has progressed most rapidly in cardiomyocytic lineages where intensive effort has gone into understanding transcriptional networks at the epigenetic level.² In cardiomyocytic lineages, multiple noncoding ribonucleic acids (RNAs) have been identified that coordinate protein complexes to direct promoter modification or other remote transcriptional enhancers. Despite significant progress in the identification of the genetic basis of aortic aneurysms, the full range of chromatin modifications that affect disease progression is just

On behalf of the Cardiolinc™ network (www.cardiolinc.org).

DOI https://doi.org/10.1055/s-0038-1639610.
ISSN 2325-4637.

License terms

Copyright © 2018 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
Tel: +1(212) 584-4662.
beginning to be investigated. This review will cover the known literature regarding epigenetic control of ascending thoracic aortic aneurysm (TAA) and ascending aortic dissection (AAD), and highlight opportunities for future research in this important topic.

**Thoracic Aortic Aneurysm and Dissection: Pathophysiology**

Dilating remodeling of arterial tissues is defined as the structural consequence of dysregulated biological activities controlling the ECM and cell homeostasis within the wall. Aneurysms, regardless of their localization, are characterized by breakdown of the ECM, and aortic smooth muscle cell (aSMC) loss, leading to progressive dilation of the arteries, thinning of the medial layer, and, eventually leading to rupture of the arterial wall. Risk factors for aortic aneurysm are dependent on the regional propensity of the affected segment. Descending thoracic aortic aneurysm (DTAA) demonstrates a pathology characterized by atheroma, aSMC disarray and apoptosis, intense phagocytosis, and intraluminal thrombus usually observed in abdominal aortic aneurysms (AAA). Enzymatic degradation of the aortic ECM leads to structural weakening, dilation, and eventually rupture if left untreated.7 A large proportion of patients with DTAA also coexpress AAA. In contrast, the ascending thoracic aorta is relatively protected. Instead, TAAAs have a pathologic appearance characterized by a leukocyte-independent “mediated degeneration” in which medial aSMCs play the major role.

Thoracic aortic aneurysm, a progressive dilation of the thoracic ascending aorta, is a chronic pathology involving an imbalance between proteolytic degradation of the ECM and wall compensating resistance to proteolytic injury,4 involving aSMC adaptive capacities (phenotypic switches, mainly from contractile to synthetic state). TAA associates with highly penetrant genetic conditions that segregate with single genes,8 but can also have a degenerative etiology in elderly patients, or be associated with bicuspid aortic valves, in which a specific hemodynamic disorder could play an important role.6 Whatever the etiology, hemodynamics, including high shear stress and arterial blood pressure, play a direct or indirect role in progressive dilation or acute tear.

The identity of genes mediating TAA often represents ECM components or regulators and genes required for the contractile function of aSMC. Increased expression of matrix-degrading enzymes, mucoid accumulation, and aSMC apoptosis are commonly noted in most forms of aneurysmal disease. Disruption of structural ECM components such as collagens and elastin is a commonly accepted mechanism of aneurysm pathogenesis. It comes as no surprise, therefore, that mutations that directly influence the ECM components can cause aneurysm. Examples include mutations in ELN,7 encoding elastin, COL3A1,8 encoding collagen type 3-α1, microfibril-associated protein 5,9 or FBN1, encoding fibrillin1, and responsible for Marfan syndrome.10 Additionally, mutations in genes encoding proteins required for elastogenesis and collagen metabolism such as EFEMP211 and LOX12 promote TAA. In these disorders, altered assembly or decreased expression of matrix components results in weakness of the aortic media.

In addition to genetic changes that directly alter ECM components, human mutations have been discovered that interfere with vascular smooth muscle-mediated aortic homeostasis in genes encoding members of the smooth muscle contraction apparatus, such as MYH11,13 encoding smooth muscle myosin and ACTA2,14 encoding α-smooth muscle actin, and PRKG-1,15 encoding type I cGMP-dependent protein kinase. Mutations are commonly encountered in genes encoding the various members of the canonical transforming growth factor β (TGF-β) signaling cascade such as TGF-β receptors TGFBR1 and TGFBR2,16 their cognate ligands TGF-β2,17 TGF-β3,18 and SMAD3, an intracellular effector of TGF-β signaling.19 Mutations in TGF-β receptors are responsible for the Loeys-Dietz syndrome.16

Aortic dissection is an acute intramural rupture, which can occur in a normal or moderately dilated aorta,20 without compensatory mechanisms. TAA and AAD correspond respectively to a progressive or acute loss of the ability of the arterial wall to withstand the arterial blood pressure.

TAA and AAD share common etiologies, including monogenic diseases in young patients.13,21 They also feature common pathological signatures, including aSMC cell disappearance, areas of mucoid degeneration,22 and degradation of collagen and elastic fibers.23 Overall, TAA and AAD develop through interactions between numerous factors, including genetics—from mutations causing Mendelian traits to genetic susceptibility, environmental factors such as specific hemodynamic conditions,24 and aSMC phenotypic changes, some of which are induced by epigenetic modifications.

**Epigenetics: General Concepts**

As displayed in —Fig. 1, epigenetic modifications encompass different mechanisms: modifications of DNA-associated histone proteins, DNA methylation, and noncoding RNAs-mediated modifications.25 These mechanisms target either DNA molecules, transcriptional machinery, or transcription products, resulting in modulation of gene expression and consequent protein synthesis.

Histones are DNA-associated proteins responsible for chromatim compaction. They are prone to modifications such as acetylation, methylation, phosphorylation, adenosine diphosphate-riboseylation, and sumoylation that generally occur on specific amino acid residues (arginine and lysine) of their N- extremity.26 Histone acetylation is associated with chromatin loosening and activates transcription, while histone methylation can either activate or repress transcription.27

Performed by DNA methyltransferases,28 DNA methylation forms a covalent but reversible bond between a methyl group and the DNA base cytosine, resulting in the production of 5-methylcytosine, sometimes considered as the “fifth base” of DNA. DNA methylation is commonly associated with repression of transcription. Methylated DNA can interact with other epigenetics changes as histone-code modifications.29

Noncoding RNAs are defined as RNA molecules lacking protein-coding potential. They are generally classified according to their size: small noncoding RNAs contain less than 200 nucleotides, while long noncoding RNAs (lncRNAs)
contain at least 200 base pairs. Different types of small noncoding RNAs have been characterized, among which 20-nucleotides-long microRNAs (miRNAs) predominate. MiRNAs possess a seed sequence (6 to 8 nucleotides in length), homologous with the 3′ untranslated region of their target genes. The binding of miRNAs to their target gene through base complementarity results in repression of the expression of the target gene. This repression occurs through messenger RNA (mRNA) degradation when the complementarity between miRNAs and target genes is complete and through inhibition of translation when this complementarity is partial. Importantly, several miRNAs can bind the same mRNA and a single miRNA can bind different mRNAs, attesting for the complexity of gene regulation by miRNAs.

The mechanisms of gene regulation by lncRNAs are more complex and diverse than miRNAs. LncRNAs can act as signal, decoy, guide, scaffold, or enhancer. Some lncRNAs mediate their effects by guiding or recruiting proteinaceous complexes to initiate transcription. The lncRNA Xist modulates gene expression by regulation of imprinting. The lncRNA named CDR1-AS is circular and acts as a miRNA-sponge, preventing the binding of miRNAs to target genes, hence favoring their expression. LncRNAs can also compete with other genes or RNA transcripts, acting as competitive endogenous RNA.

The presence of miRNAs in the circulation was revealed almost a decade ago and a plethora of studies on the potential of miRNAs for use as biomarkers of cardiovascular disease rapidly emerged. The biomarker potential of circulating lncRNAs has been more recently evidenced. Circular RNAs, which are more stable than their linear counterparts due to resistance to exonuclease degradation, also appear to possess an interesting biomarker potential.

**Epigenetics in Thoracic Aortic Aneurysm Disease**

**Histone Modifications**

Experimental studies reported an activation of TGF-β in aneurysms related to Marfan syndrome. TGF-β signaling in syndromic and nonsyndromic aneurysmal diseases was investigated in different types of aneurysmal ascending aortic specimens. The TGF-β1 mRNA was not significantly changed. In contrast, the amounts of TGF-β1 protein retained within and released by an aneurysmal media layer were greater than for a healthy aortic media layer. This observation fitted with the observed increase in LTBP-1 mRNA and protein, associated with the increase in ECM protein turnover reported in TAA. This was associated with higher levels of Smad2 mRNA, phosphorylated Smad2 protein, and nucleus translocation in the ascending aortic wall from all types of aneurysm. Activation of TGF-β pathway was correlated with the degree of elastic fiber fragmentation. Surprisingly, there was no consistent colocalization between the nuclear location of phospho-Smad2 and extracellular TGF-β staining. This first study highlights independent dysregulations of TGF-β retention and Smad2 expression in TAA, whatever their etiologies, suggesting a non-TGF-β dependent activation and nuclear translocation of Smad2 in TAA.

In a second study performed on human aortic samples, including TAAs of different etiologies and normal aortas from which tissue extracts and aSMCs and fibroblasts were obtained in primary cultures, it was observed that all types of TAA share a complex dysregulation of Smad2 signaling, independent of TGF-β1 in TAA-derived aSMCs. The Smad2 dysregulation was characterized by an aSMC-specific (not seen in fibroblasts) heritable activation and overexpression of...
Smad2, compared with normal aortas. The cell specificity and heritability of this overexpression of Smad2 suggested the implication of an epigenetic control. Using chromatin immunoprecipitation assay, the authors showed that Smad2 overexpression in TAA involves increases in H3K9/14 acetylation and H3K4 methylation. These results demonstrated the heritability, cell specificity, and independence with regard to TGF-β1 and genetic backgrounds of the Smad2 dysregulation in thoracic aneurysms and the involvement of epigenetic mechanisms regulating histone marks in this process.

In a third study, the histone-modifying enzymes, transcription factors, and cofactors responsible for Smad2 promoter activation in aSMC from TAA patients were explored to understand the mechanisms regulating Smad2 overexpression. It was shown that Smad2 promoter activation is driven by the recruitment of a multipartner complex, including the transcription factor p53 and histone acetyltransferases. Remarkably, the transcriptional regulatory network of the Smad2 promoter was dramatically altered in human aneurysmal aSMCs in vitro and in situ with a switch from Myc-dependent repression of Smad2 in normal vessel to a p53-dependent constitutive activation of Smad2 in aneurysms. Furthermore, histone acetyltransferases p300 and P300/CBP-associated proteins played a major role in Smad2 promoter activation by acting on histone acetylation and p53 recruitment. These results provided evidence for a major role of p53 and the complex composed of histone acetyltransferases p300 and p300/CBP-associated proteins in Smad2 activation in human aneurysmal aSMCs.

In a fourth study, protease nexin-1 (PN-1) and plasminogen activator inhibitor-1 (PAI-1), both inhibitors of serine-protease were overexpressed in medial tissue extracts and primary aSMCs from TAA compared with acute dissections of ascending aortic and healthy aorta. Furthermore, TGF-β increased PN-1 expression in control but not in aneurysmal aSMCs. PN-1 and PAI-1 overexpression by aneurysmal aSMCs was associated with increased Smad2 binding on their respective gene promoters. This phenomenon was restricted to aneurysms and not observed in acute dissections. Thus, epigenetically regulated PN-1 overexpression promotes development of an anti-proteolytic aSMC phenotype which might favor progressive aneurysmal dilation. Absence of this counter regulation may lead to acute wall rupture (dissection, Fig. 2).

### DNA Methylation

A genome-wide DNA methylation study comparing aortic tissues from patients with two different etiologies of TAA, bicuspid and tricuspid aortic valves, revealed that several genes involved in cardiovascular development were differentially methylated, suggesting that DNA methylation may be involved in TAA development and dissection.

### MicroRNAs

Although the functional contribution of miRNAs to the development of TAA and progression toward dissection is still poorly characterized, some associations between miRNAs expression levels, TAA and AAD, have been reported (Table 1).

**MicroRNA Profiles**

Technological developments of high-throughput approaches such as microarray facilitated the characterization of disease-associated miRNA profiles.

Using microarray and quantitative polymerase chain reaction (PCR), a panel of four up-regulated and three down-regulated miRNAs was identified in six aortic tissues from patients with TAA.

---

**Fig. 2** Schematic representation of the differential biology between chronic dilation of the aorta (aneurysm) and acute intraparietal rupture (dissection). The progressive development of chromatin remodeling in aortic smooth muscle cells (aSMC) in response to small dilation or matrix proteolytic injury could reduce the risk of acute rupture. Abbreviations: PN-1, protease nexin-1, PAI-1, plasminogen activator inhibitor-1.
| ID          | AAD aortic tissue | TAA aortic tissue | Reference | Expression versus control | Technology | Reference |
|-------------|-------------------|-------------------|-----------|---------------------------|------------|-----------|
| miR-1       | ↓                 | Microarray        | 51        | ↓                         | Microarray, PCR | 52,54     |
| miR-15a     | ↓                 | Microarray        |           | ↑                         | Microarray | 53        |
| miR-21      | ↓                 | Microarray, PCR   | 51        | ↓                         | Microarray | 53,54     |
| miR-21a     | ↑                 | Microarray        |           | ↑                         | Microarray | 53        |
| miR-22      | ↓                 | Microarray, PCR   | 51        | ↓                         | Microarray | 53,54     |
| miR-25      | ↑                 | Microarray        |           | ↑                         | Microarray | 53        |
| miR-29a     | ↓                 | Microarray        | 51        | ↓                         | Microarray, PCR | 52,54     |
| miR-29b     | ↑                 | Microarray        |           | ↑                         | Microarray; PCR | 53,57     |
| miR-30c     | ↓                 | PCR               |           | ↑                         | PCR        | 54        |
| miR-125a-3p | ↓                 | Microarray        |           | ↑                         | Microarray | 53        |
| miR-126-3p  | ↑                 | Microarray        |           | ↑                         | Microarray; PCR | 53,54     |
| miR-128     | ↑                 | Microarray        |           | ↑                         | Microarray | 53        |
| miR-133a    | ↓                 | Microarray        | 51        | ↓                         | Microarray, PCR | 52-54     |
| miR-133b    | ↓                 | Microarray        | 51        | ↓                         | Microarray | 53        |
| miR-138-1a  | ↑                 | Microarray        | 51        | ↑                         | Microarray | 53        |
| miR-142-5p  | ↑                 | Microarray        |           | ↑                         | Microarray | 53        |
| miR-143     | ↓                 | Microarray, PCR   | 51        | ↓                         | PCR        | 67        |
| miR-145     | ↓                 | Microarray, PCR   | 51        | ↓ ; ↑                     | Microarray; PCR | 53,54,66,67|
| miR-146b-5p | ↑                 | Microarray        |           | ↑                         | PCR        | 53,54     |
| miR-155     | ↑                 | Microarray        |           | ↑                         | PCR        | 54        |
| miR-183a    | ↑                 | Microarray, PCR   | 51        | ↑                         | Microarray | 53        |
| miR-204     | ↓                 | PCR               |           | ↓                         | PCR        | 54        |
| miR-422a    | ↑                 | Microarray        |           | ↑                         | Microarray | 53        |
| miR-433     | ↑                 | Microarray, PCR   | 51        | ↑                         | Microarray | 53        |
| miR-486-5p  | ↓                 | Microarray        |           | ↓ ; ↑                     | Microarray; PCR | 53,54     |
| miR-487b    | ↑                 | Microarray        |           | ↑                         | Microarray | 53        |
| miR-491-3p  | ↑                 | Microarray, PCR   | 51        | ↑                         | Microarray | 53,57     |
| miR-553     | ↑                 | Microarray        |           | ↑                         | Microarray | 53        |
| miR-638     | ↑                 | Microarray        |           | ↑                         | Microarray | 53,54     |
| miR-940     | ↓                 | Microarray        |           | ↓                         | Microarray | 53        |
| miR-193a-3p; | ↑                 | Microarray        |           | ↑                         | Microarray | 53        |
| miR-768-5p;  | ↓                 | Microarray        | 51        | ↓                         | Microarray | 53        |
| miR-886-5p;  | ↑                 | Microarray        |           | ↑                         | Microarray | 53        |
| miR-195;    | ↓                 | PCR               |           | ↑                         | PCR        | 54        |
| miR-101;    | ↑                 | Microarray        |           | ↑                         | Microarray | 53        |
| miR-140-5p;  | ↓                 | PCR               |           | ↓                         | PCR        | 54        |
| miR-744     | ↑                 | Microarray        |           | ↑                         | Microarray | 53        |

Abbreviations: AAD, ascending aortic dissection; PCR, polymerase chain reaction; TAA, thoracic aortic aneurysm.

*aOnly in males.

bOnly in females.

↑: upregulated in disease versus control.

↓: downregulated in disease versus control.

Underlined: miRNAs differentially expressed in TAA and AAD.

5
AAD patients compared with six control subjects. In another study, four miRNAs were down-regulated in aortic tissues from TAA patients compared with control subjects, and their expression levels were inversely correlated with aortic diameter. Also with microarray, a set of 16 miRNAs was found to be regulated in 10 nonfamilial and nonsyndromic aneurysmal ascending aorta compared with 10 control aorta. Interestingly, gender-associated differences in miRNA profiles were observed in this study. Yet, no validation by PCR was reported. More recently, 6 up-regulated and 2 down-regulated miRNAs were observed in this study. Yet, no validation by PCR was reported. Noteworthy, even though two different diseases (AAD and TAA) were investigated in these four studies, at least nine miRNAs (miR-22/-29a/-133a/-133b/-138-3p/-193a-5p/-491-3p) showed similar expression patterns (see Table 1). Considering that TAA and AAD display similar features, these studies support the involvement of miRNAs in TAA and AAD pathogenesis. However, miR-1/-30c/-2/-145/-204/-331–3p were up-regulated in human aortic tissue samples from patients with TAA compared with DTAA. Since TAA and DTAA possess different clinical features and etiologies, such differences of miRNA profiles strengthen the concept that miRNAs may play specific roles in TAA and DTAA pathogenesis.

Investigation of the functional role of miRNAs in TAA and AAD remains difficult in human aortic tissues in situ. Gender-associated differences need to be considered. The use of primary human aSMC and experimental models in mice allowed a better characterization of the mechanisms of action of miRNAs, as detailed hereafter.

**MiR-29 Family**

MiR-29 family contains three members, miR-29a/-29b/-29c, all involved in fibrosis. MiR-29b was highly expressed in human aSMC compared with endothelial cells and monocytes. Its expression was higher in aorta from TAA patients compared with healthy controls, whereas expression of miR-29a and miR-29c was comparable between the two groups. In humans, however, miR-29a expression was decreased during TAA formation. In mice, miR-29 family members were overexpressed in aorta from fibulin-4 deficient animals. MiR-29b was also overexpressed in angiotensin II-infused mice and its silencing with locked nucleic acid (LNA)-modified antisense oligonucleotides inhibited angiotensin II-triggered aortic dilation. MiR-29b was up-regulated in the ascending aorta of Marfan Fbn1<sup>C1039G/+</sup> mice and its inhibition with LNA-modified antisense oligonucleotides prevented aneurysm development, reduced apoptosis in aortic wall, and increased ECM components synthesis.

In vitro, miR-29b induced aSMC migration by inhibiting DNA methyltransferase 3 that negatively regulates matrix metalloproteinases 2 and 9 expression. MiR-29b directly targets the genes encoding the antiapoptotic proteins MCL1 (a member of the BCL2 family of apoptosis regulators) and KLF4 (Kruppel-like factor 4). KLF4 is a transcription factor involved in aSMC proliferation and is activated by Sp1. MiR-29 family members also down-regulate the expression of several genes coding for ECM proteins such as collagen 1a1, 1a2, 3a1, eln1, fn1, and Adams7. TGF-β1 stimulation increased miR-29b expression in aSMC from Fbn1<sup>C1039G/+</sup> mice but not from wild-type mice. This stimulation reduced nuclear factor kappa B (NFκB) activity and, since miR-29b expression is inhibited by NFκB in ascending aorta of young Fbn1<sup>C1039G/+</sup> mice, the authors proposed that up-regulation of miR-29b expression by TGF-β1 may involve the NFκB pathway.

These studies support a therapeutic potential for miR-29b for the prevention of TAA expansion, acting through modulation of aSMC synthetic phenotypic switch and ECM composition. The cross-talk between miR-29b and TGF-β is consistent with a role for miR-29b in the pathogenesis of conditions due to TGF-β pathway alteration, not limited to TAA and AAD. The observation that TGF-β impacts miR-29b expression suggests that TAA and AAD pathogenesis is controlled by complex epigenetic mechanisms that remain to be fully deciphered.

Intriguingly, in aorta from young Fbn1<sup>C1039G/+</sup> mice, losartan administration reduced aneurysm formation and miR-29b expression. Furthermore, expression of miR-29 family members was increased in aorta of aged mice compared with young mice. These observations may explain, at least in part, the heterogeneity of results obtained from human studies, mostly negative. Medication and age are certainly confounding factors that need to be taken into account in future clinical studies.

**MiR-143/-145 Family**

MicroRNA-143 and miR-145 are expressed from the same bicistronic precursor. Both miRNAs were down-regulated in aorta from AAD patients compared with controls and miR-145 was up-regulated in TAA compared with DTAA. In another study, miR-145 expression was higher in TAA tissues compared with control tissues and was positively correlated with collagen III levels and aortic diameter. Elsewhere, miR-143/-145 expression was deficient in aortic tissues from TAA patients compared with controls. These discrepancies may be attributed to technical bias (use of microarray or PCR to measure miRNAs) or differences between patient cohorts and disease etiology.

In mice, miR-143 and miR-145 were enriched in aorta compared with other organs. Homozygous miR-143/-145 knocked-out mice showed altered aortic structure compared with the wild-types, as characterized by diminution of medial thickness, and aSMC dedifferentiation and migration toward the intima.

In vitro, miR-145 has been proposed as a phenotypic marker of vascular smooth muscle cells (vSMC). MiR-143/-145 appear to play an important role in vSMC phenotypic switch since their inhibition increased cell migration and decreased proliferation. Furthermore, miR-143/-145 up-regulation increased the expression of vSMC differentiation markers. The effects of miR-145 on vSMC are mediated by modulation of the TGF-β pathway and targeting of KLF4 and KLF5. Using cocultured vascular endothelial cells and vSMC, a communication involving exosomes containing miR-143/-145 and transferring from endothelial cells to vSMC could be demonstrated.
Despite some heterogeneity observed in human studies, miR-143/-145 family is apparently deeply involved in the regulation of aSMC biology and ECM composition. Since aSMC phenotypic switch and ECM alterations are critical in aortic media dysfunction, miR-143 and miR-145 may play important roles in TAA and AAD pathogenesis that could be interesting for therapeutic purposes.

MicroRNAs in aSMC Phenotypic Switch
Due to the importance of aSMC phenotypic switch in the pathogenesis of TAA and AAD, the following chapter focuses on miRNAs (Fig. 3) and their target genes (Table 2) known to regulate this switch.

- **MicroRNAs promoting aSMC differentiation.** MiR-1 expression was induced by myocardin in aSMC, targeted KLF4, and induced aSMC differentiation from embryonic stem cells. MiR-133 repressed Sp1 (which activates KLF4), resulting in maintenance of aSMC in a differentiated status. MiR-133 also inhibited aSMC migration, acta2 and srf expression, and was associated with an increase in myh11 expression. MiR-663 and miR-424 induced the expression of aSMC differentiation markers (acta2; myh11) and decreased aSMC migration. MiR-221 and miR-222 are two close homologous miRNAs sharing the same seed sequence. They are highly expressed in aSMC, inducing not only their proliferation but also their migration, and inhibiting their apoptosis, presumably through modulation of their target genes p27 (Kip1), p57 (Kip2), and c-Kit. Interestingly, miR-221/-222 had opposite effects on endothelial cells compared with aSMC. MiR-26a targets the TGF-β/BMP (bone morphogenetic protein) pathway, thereby inhibiting aSMC apoptosis and differentiation, and activating proliferation and migration. MiR-146a and miR-155 induced aSMC migration and repressed apoptosis. MiR-31 was strongly expressed in aSMC and induced their proliferation, probably through modulation of cellular repressor of E1A-stimulated genes and acta2. MiR-181b induced proliferation, and migration of aSMC through the PI3K and MAPK pathways.

- **MicroRNAs promoting phenotype switch.** The role of miR-21 in aSMC phenotype switch is less clear since it appears to be able to promote aSMC differentiation as well as proliferation, which is considered as a feature of dedifferentiation. Likewise, miR-24 inhibited aSMC proliferation and migration but repressed the expression of contractile gene markers.

Overall, the differential expression of multiple miRNAs in aneurysmal aortic tissues, as well as their functional involvement in aSMC biology and ECM composition, strongly supports their role in the pathogenesis of TAA and AAD. The challenge resides in the differentiation between simple bystanders and miRNAs that actively contribute to the disease, the latter category containing the most interesting therapeutic candidates. MiR-29b appears to be such a good candidate.

To our knowledge, the biomarker potential of circulating miRNAs has not been studied in the context of TAA. The potential use of circulating miRNAs as markers of AAA and aneurysm growth has only recently been reported. Being able to predict dissection with a simple blood test, based on miRNA measurements, for instance, would represent a major achievement.
Long Noncoding RNAs
Contrarily to miRNAs, a few studies have addressed the association between IncRNAs and TAA. The IncRNA AK056155 was up-regulated in serum and aortic tissue samples from patients with Loeys–Dietz syndrome compared with controls.\(^{89}\) Since these patients generally develop TAA, it is conceivable that AK056155 is also associated with TAA. However, all patients with Loeys–Dietz syndrome enrolled in this study had AAA, precluding evaluation of the association between AK056155 and TAA. Another lncRNA, named HIF1α-AS1 for its localization on the antisense strand of the gene coding the hypoxia inducible factor 1α, was strongly up-regulated in serum of patients with thoraco-AAA.\(^{90}\) HIF1α-AS1 down-regulation in palmitic acid-treated aSMC inhibited apoptosis and this effect was associated with a decrease in caspase-3, -8, and bcl 2 expression.\(^{90,91}\)

Mice lacking the lncRNA GAS5 display a thickening of the aortic media.\(^{92}\) GAS5 is expressed in aortic wall, endothelial cells, and aSMC. In aSMC, its down-regulation increased viability and proliferation and lowered expression of aSMC markers.\(^{92}\) Interestingly, GAS5 may act as paracrine mediator since conditioned medium obtained from endothelial cells overexpressing GAS5 induced a decrease in proliferation and migration of aSMC.\(^{92}\) Knocking out the lncRNA RNCR3 in mice lowered aSMC proliferation, an effect attributed to a competition for miR-185–5p binding.\(^{93}\)

In vitro experiments revealed that, like miRNAs, IncRNAs affect aSMC proliferation and migration (► Fig. 3). The IncRNA ANRIL (CDKN2B antisense RNA 1) induced aSMC proliferation and up-regulated some genes involved in TAA such as eln and col3a1.\(^{94}\) MEG3 reduced proliferation and increased migration of aSMC, effects accompanied by p53 and mmp2 overexpression.\(^{95}\) H19 induced aSMC proliferation, an effect mediated by miR-675.\(^{96}\) LincRNA-p21 inhibits aSMC proliferation and apoptosis by regulating p53 activity.\(^{97}\)

SENCR is highly expressed in aSMC and its down-regulation repressed the expression of aSMC markers and increased cell migration.\(^{98}\) The role of IncRNAs in TAA is only emerging. The observation that some IncRNAs are present in blood supports a potential use as biomarkers. A deeper characterization of the functional involvement and biomarker potential of IncRNAs in TAA and AAD is warranted.

### Conclusion and Future Directions
Genetic alterations critically account for the development of TAA and the progression toward dissection. However, other etiologies of TAA or AAD such as degenerative TAA or AAD occurring on medium-sized aorta are unrelated to any known DNA polymorphism. In this context, epigenetic modifications, which do not change DNA sequence, may also trigger, or at least contribute to, TAA and AAD. Several lines of evidence strongly support a causative role of epigenetic modifications and noncoding RNAs in the pathogenesis of TAA and AAD.

Since epigenetic modifications may occur under the influence of environmental changes such as hemodynamic...
modifications, it would be interesting to address whether chromatin remodeling mediated by histone modifications is related to the hemodynamic modifications featured in TAA. Indeed, the dilation (increased radius, r) observed in TAA is associated with a decreased media thickness (h), leading to a dramatic increase in wall tension (T) at a constant blood pressure (P), according to the Laplace’s law (T = Pr/2h). The nuclear envelope is mechanically coupled to mechanotransduction through aSMC adhesion to matrix, coupling of integrins to actin, intermediate filaments (tensegrity) and linkers of nucleoskeleton to cytoskeleton. It has been proposed that the mechanical environment impacts the chromatin status of aSMC, thereby controlling vascular gene expression and function. It is, therefore, likely that the increased wall tension in TAA leading to altered mechanotransduction signaling between the matrix and the nucleus will impact chromatin remodeling in aSMC, an issue that has not been addressed. In addition, since chromatin remodeling is associated with chronic progressive dilation but not with acute intraparietal rupture (dissection without important dilation), chromatin remodeling in aSMC could be a hallmark of TAA as compared with dissecting aortas. The impact of noncoding RNAs on TAA and AAD pathogenesis is far from being well characterized. Increasing evidences show that both short and lncRNAs interact to regulate chromatin remodeling, aSMC phenotype, and ECM composition, sometimes through mediation of cell–cell communication. Since miRNAs and IncRNAs are present in the blood, it is conceivable that they may emanate, actively or passively, from the diseased vascular wall and inform about its stability or propensity to rupture. The possibility that noncoding RNAs could be used as biomarkers of TAA and dissection is attractive and remains to be tested. Additional research is warranted to reach a better knowledge of the epigenetic mechanisms gearing TAA development and aneurysm rupture. Several studies reported here showed the involvement of noncoding RNAs in TAA and dissection. However, their role in the pathogenesis of these diseases is only partly understood. Increasing interest is observed toward epigenetic changes can be only partly understood. Increasing interest is observed toward DNA methylation and histone modifications, it would be interesting to address whether chromatin remodeling mediated by histone modifications is related to the hemodynamic modifications featured in TAA. Indeed, the dilation (increased radius, r) observed in TAA is associated with a decreased media thickness (h), leading to a dramatic increase in wall tension (T) at a constant blood pressure (P), according to the Laplace’s law (T = Pr/2h). The nuclear envelope is mechanically coupled to mechanotransduction through aSMC adhesion to matrix, coupling of integrins to actin, intermediate filaments (tensegrity) and linkers of nucleoskeleton to cytoskeleton. It has been proposed that the mechanical environment impacts the chromatin status of aSMC, thereby controlling vascular gene expression and function. It is, therefore, likely that the increased wall tension in TAA leading to altered mechanotransduction signaling between the matrix and the nucleus will impact chromatin remodeling in aSMC, an issue that has not been addressed. In addition, since chromatin remodeling is associated with chronic progressive dilation but not with acute intraparietal rupture (dissection without important dilation), chromatin remodeling in aSMC could be a hallmark of TAA as compared with dissecting aortas. The impact of noncoding RNAs on TAA and AAD pathogenesis is far from being well characterized. Increasing evidences show that both short and lncRNAs interact to regulate chromatin remodeling, aSMC phenotype, and ECM composition, sometimes through mediation of cell–cell communication. Since miRNAs and IncRNAs are present in the blood, it is conceivable that they may emanate, actively or passively, from the diseased vascular wall and inform about its stability or propensity to rupture. The possibility that noncoding RNAs could be used as biomarkers of TAA and dissection is attractive and remains to be tested. Additional research is warranted to reach a better knowledge of the epigenetic mechanisms gearing TAA development and aneurysm rupture. Several studies reported here showed the involvement of noncoding RNAs in TAA and dissection. However, their role in the pathogenesis of these diseases is only partly understood. Increasing interest is observed toward epigenetic changes can be only partly understood. Increasing interest is observed toward DNA methylation and histone modifications, it would be interesting to address whether chromatin remodeling mediated by histone modifications is related to the hemodynamic modifications featured in TAA. Indeed, the dilation (increased radius, r) observed in TAA is associated with a decreased media thickness (h), leading to a dramatic increase in wall tension (T) at a constant blood pressure (P), according to the Laplace’s law (T = Pr/2h). The nuclear envelope is mechanically coupled to mechanotransduction through aSMC adhesion to matrix, coupling of integrins to actin, intermediate filaments (tensegrity) and linkers of nucleoskeleton to cytoskeleton. It has been proposed that the mechanical environment impacts the chromatin status of aSMC, thereby controlling vascular gene expression and function. It is, therefore, likely that the increased wall tension in TAA leading to altered mechanotransduction signaling between the matrix and the nucleus will impact chromatin remodeling in aSMC, an issue that has not been addressed. In addition, since chromatin remodeling is associated with chronic progressive dilation but not with acute intraparietal rupture (dissection without important dilation), chromatin remodeling in aSMC could be a hallmark of TAA as compared with dissecting aortas. The impact of noncoding RNAs on TAA and AAD pathogenesis is far from being well characterized. Increasing evidences show that both short and lncRNAs interact to regulate chromatin remodeling, aSMC phenotype, and ECM composition, sometimes through mediation of cell–cell communication. Since miRNAs and IncRNAs are present in the blood, it is conceivable that they may emanate, actively or passively, from the diseased vascular wall and inform about its stability or propensity to rupture. The possibility that noncoding RNAs could be used as biomarkers of TAA and dissection is attractive and remains to be tested. Additional research is warranted to reach a better knowledge of the epigenetic mechanisms gearing TAA development and aneurysm rupture. Several studies reported here showed the involvement of noncoding RNAs in TAA and dissection. However, their role in the pathogenesis of these diseases is only partly understood. Increasing interest is observed toward DNA methylation and histone modification. New insights into their role in TAA and dissection pathogenesis are expected to emerge in the upcoming years. Since epigenetic changes can be modulated, this may lead to novel tools for better diagnosis and treatment of these severe conditions. Conflicts of Interest The authors declare no conflict of interest related to this article.

Acknowledgements
None.

References
1 Benoist EJ, Blaha MJ, Chiuve SE, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: a report from the American Heart Association. Circulation 2017;135(10): e146–e603
2 Bruneau BG. Epigenetic regulation of the cardiovascular system: introduction to a review series. Circ Res 2010;107(03):324–326
3 Kim JB, Kim K, Lindsay ME, et al. Risk of rupture or dissection in descending thoracic aortic aneurysm. Circulation 2015;132(17): 1620–1629
4 Jondeau G, Michel JB, Boileau C. The translational science of Marfan syndrome. Heart 2011;97(15):1206–1214
5 Vapnik JS, Kim JB, Isselbacher EM, et al. Characteristics and outcomes of ascending versus descending thoracic aortic aneurysms. Am J Cardiol 2016;117(10):1683–1690
6 Michela H, Della Corte A, Prakash SK, Milewicz DM, Evangelista A, Enriquez-Sarano M, Bicuspid aortic valve aortopathy in adults: incidence, etiology, and clinical significance. Int J Cardiol 2015;201:400–407
7 Szabo Z, Crepeau MW, Mitchell AL, et al. Aortic aneurysm disease and cutis laxa caused by defects in the elastin gene. J Med Genet 2006;43(03):255–258
8 Superti-Furga A, Gugler E, Gitzelmann R, Steinmann B. Ehlers-Danlos syndrome type IV: a multi-exon deletion in one of the two COL3A1 alleles affecting structure, stability, and processing of type III procollagen. J Biol Chem 1988;263(13):6226–6232
9 Barbier M, Gross MS, Aubart M, et al. MFAP5 loss-of-function mutations underscore the involvement of matrix alteration in the pathogenesis of familial thoracic aortic aneurysms and dissections. Am J Hum Genet 2014;95(06):736–743
10 Magenis RE, Maslen CL, Smith L, Allen L, Sakai IY. Localization of the fibrillin (FBN) gene to chromosome 15, band q21.1. Genomics 1991;11(02):346–351
11 Dasouki M, Markova D, Garola R, et al. Compound heterozygous mutations in fibrillin-4 causing neonatal lethal pulmonary artery occlusion, aortic aneurysm, arachnodactyly, and mild cutis laxa. Am J Med Genet A 2007;143A(22):2635–2641
12 Guo DC, Regalado ES, Gong L, et al; University of Washington Center for Mendelian Genomics. LOX mutations predispose to thoracic aortic aneurysms and dissections. Circ Res 2016;118(06):928–934
13 Zhu L, Vanckx R, Khau Van Kien P, et al. Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet 2006;38(03):343–349
14 Guo DC, Pannu H, Tran-Fadulu V, et al. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat Genet 2007;39(12):1488–1493
15 Guo DC, Regalado E, Casteel DE, et al; GenFAC Registry Consortium; National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project. Recurrent gain-of-function mutation in PRKG1 causes thoracic aortic aneurysms and acute aortic dissections. Am J Hum Genet 2013;93(02): 398–404
16 Loey S, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005;37(03):275–281
17 Lindsay ME, Scheipers D, Bolar NA, et al. Loss-of-function mutations in TGFBR2 cause a syndromic presentation of thoracic aortic aneurysm. Nat Genet 2012;44(08):922–927
18 Bertoli-Avella AM, Gillis E, Morisaki H, et al. Mutations in a TGF-β ligand, TGFβ3, cause syndromic aortic aneurysms and dissections. J Am Coll Cardiol 2015;65(13):1324–1336
19 van de Laar IM, Oldenburg RA, Pals G, et al. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet 2011;43(2):121–126
20 LeMaire SA, Russell L. Epidemiology of thoracic aortic dissection. Nat Rev Cardiol 2011;8(2):103–113
21 Boileau C, Guo DC, Hanna N, et al; National Heart, Lung, and Blood Institute (NHLBI) Go Exome Sequencing Project. TGFβ2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nat Genet 2012;44(8):916–921
22 de Figueiredo Borges L, Martelli H, Fabre M, Touat Z, Jondeau G, Michel JB. Histopathology of an iatrogenic aneurysm in a case of Menkes disease. Pediatr Dev Pathol 2010;13(3):247–251
23 de Figueiredo Borges L, Jaldin RG, Dias RR, Stolf NA, Michel JB, Gutierrez PS. Collagen is reduced and disrupted in human aortic aneurysms and dissections of ascending aorta. Hum Pathol 2008;39(3):437–443
24 Bäck M, Gasser TC, Michel JB, Caligiuri G. Long noncoding RNAs in cardiac development and ageing. Nat Rev Cardiol 2015;12(7):415
25 de Figueiredo Borges L, Gomez D, Quintana M, et al. Fibrinolytic activity is associated with presence of cystic medial degeneration in aneurysms of the ascending aorta. Histopathology 2010;57(6):917–932
26 Jin B, Li Y, Robertson KD. DNA methylation: superior or suboptimal epigenetic marker for risk prediction of cardiovascular disease? Trends Cardiovasc Med 2011;21(6):172–177
27 Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet 2000;9(16):2395–2402
28 Lee KK, Workman JL. Histone acetyltransferase complexes: one function as effector of gene expression. Curr Opin Genet Dev 2002;12(1):86–92
29 Devaux Y, Creemers EE, Boon RA, et al; Cardiolinc network. Long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. Circ Res 2014;114(10):1569–1575
30 Boon RA, Dimmeler S. MicroRNAs and aneurysm formation. Circ Res 2011;109(10):1136–1146
31 Chen KC, Wang YS, Hu CY, et al. OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. FASEB J 2011;25(5):1718–1728
32 Mott JL, Kobayashi S, Bronk SF, Gores GJ. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007;26(42):6133–6140
33 Cushing L, Costinean S, Xu W, et al. Disruption of mir-29 leads to aberrant differentiation of smooth muscle cells selectively associated with distal lung vasculature. PLoS Genet 2015;11(5):e1005238
Liu X, Cheng Y, Chen X, Yang J, Xu L, Zhang C. MicroRNA-31 regulates smooth muscle cell function by repressing its target gene cellular repressor of E1A-stimulated genes. Exp Cell Res 2013;319(8):1165–1175

Li TJ, Chen YL, Guo CJ, Xue SJ, Ma SM, Li XD. MicroRNA 181b promotes vascular smooth muscle cells proliferation through activation of PI3K and MAPK pathways. Int J Clin Exp Pathol 2015;8(9):10375–10384

Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008;454(7200):56–61

Ja R, Cheng Y, Yue J, et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of microRNA in vascular neointimal lesion formation. Circ Res 2007;100(11):1579–1588

Yang J, Chen L, Ding J, et al. MicroRNA-24 inhibits high-glucose-induced vascular smooth muscle cell proliferation and migration by targeting HMGB1. Gene 2016;586(2):268–273

Fiedler J, Stöhr A, Gupta SK, et al. Functional microRNA library screening identifies the hypoxamir miR-24 as a potent regulator of smooth muscle cell proliferation and vascularization. Antioxid Redox Signal 2014;21(8):1167–1176

Wanhaienen A, Mani K, Yorppic E, et al. Screening of circulating microRNA biomarkers for prevalence of abdominal aortic aneurysm and aneurysm growth. Atherosclerosis 2017;256:82–88

Yu B, Liu L, Sun H, Chen Y. Long noncoding RNA AK056155 involved in the development of Loey-Dietz syndrome through AKT/PI3K signaling pathway. Int J Clin Exp Pathol 2015;8(9):10768–10775

Zhao Y, Feng G, Wang Y, Yue Y, Zhao W. Regulation of apoptosis by long non-coding RNA HIFIA-AS1 in VSMCs: implications for TAA pathogenesis. Int J Clin Exp Pathol 2014;7(11):7643–7652

Wang S, Zhang X, Yuan Y, et al. BRG1 expression is increased in thoracic aortic aneurysms and regulates proliferation and apoptosis of vascular smooth muscle cells through the long non-coding RNA HIFIA-AS1 in vitro. Eur J Cardiothorac Surg 2015;47(3):439–446

Wang YN, Shan K, Yao MD, et al. Long noncoding RNA-GASS: a novel regulator of hypertension-induced vascular remodeling. Hypertension 2016;68(3):736–748

Shan K, Jiang Q, Wang XQ, et al. Role of long non-coding RNA-RNCR3 in atherosclerosis-related vascular dysfunction. Cell Death Dis 2016;7(6):e2248

Congrains A, Kamide K, Katsuya T, et al. CVD-associated non-coding RNA, ANRIL, modulates expression of atherogenic pathways in VSMC. Biochem Biophys Res Commun 2012;419(4):612–616

Liu W, Liu X, Luo M, et al. dNK derived IFN-γ mediates VSMC migration and apoptosis via the induction of LncRNA MEG3: A role in uteroveinular transformation. Placenta 2017;50:32–39

Lv J, Wang L, Zhang J, et al. Long noncoding RNA H19-derived miR-675 aggravates restenosis by targeting PTEN. Biochem Biophys Res Commun 2017;500:730011-6

Wu G, Cai J, Han Y, et al. LncRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by enhancing p53 activity. Circulation 2014;130(17):1452–1465

Bell RD, Long X, Lin M, et al. Identification and initial functional characterization of a human vascular cell-enriched long non-coding RNA. Arterioscler Thromb Vasc Biol 2014;34(6):1249–1259

Ingber DE. Tensegrity II: How structural networks in influence cellular information processing networks. J Cell Sci 2003;116(PT 8, 116Pt 8):1397–1408

Wang N, Tytell JD, Ingber DE. Mechanotransduction at a distance: mechanically coupling the extracellular matrix with the nucleus. Nat Rev Mol Cell Biol 2009;10(1):75–82
101 Isermann P, Lammerding J. Nuclear mechanics and mechano-transduction in health and disease. Curr Biol 2013;23(24):R1113–R1121

102 Sun SG, Zheng B, Han M, et al. miR-146a and Krüppel-like factor 4 form a feedback loop to participate in vascular smooth muscle cell proliferation. EMBO Rep 2011;12(01):56–62

103 Di Gregoli K, Mohamad Anuar NN, Bianco R, et al. MicroRNA-181b controls atherosclerosis and aneurysms through regulation of TIMP-3 and elastin. Circ Res 2017;120(01):49–65

104 Kee HJ, Kim GR, Cho SN, et al. miR-18a-5p microRNA increases vascular smooth muscle cell differentiation by downregulating Syndecan4. Korean Circ J 2014;44(04):255–263

105 Li J, Zhao L, He X, Yang T, Yang K. MiR-21 inhibits c-Ski signaling to promote the proliferation of rat vascular smooth muscle cells. Cell Signal 2014;26(04):724–729

106 Yang G, Pei Y, Cao Q, Wang R. MicroRNA-21 represses human cystathionine gamma-lyase expression by targeting at specificity protein-1 in smooth muscle cells. J Cell Physiol 2012;227(09):3192–3200

107 Le Sage C, Nagel R, Egan DA, et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 2007;26(15):3699–3708

108 Davis BN, Hilyard AC, Nguyen PH, Lagna G, Hata A. Induction of microRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype. J Biol Chem 2009;284(06):3728–3738

109 Zhu XF, Shan Z, Ma JY, et al. Investigating the role of the posttranscriptional gene regulator MiR-24-3p in the proliferation, migration and apoptosis of human arterial smooth muscle cells in arteriosclerosis obliterans. Cell Physiol Biochem 2015;36(04):1359–1370